{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABSSSI",
    "query": {
      "condition": "ABSSSI"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ABSSSI&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:05:12.593Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01984684",
      "title": "Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Skin and Subcutaneous Tissue Bacterial Infections",
        "Skin Structures and Soft Tissue Infections"
      ],
      "interventions": [
        {
          "name": "delafloxacin",
          "type": "DRUG"
        },
        {
          "name": "vancomycin",
          "type": "DRUG"
        },
        {
          "name": "aztreonam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 850,
      "start_date": "2014-05",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 31,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01984684"
    },
    {
      "nct_id": "NCT02607618",
      "title": "Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Skin Structures and Soft Tissue Infections"
      ],
      "interventions": [
        {
          "name": "Iclaprim",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Motif Bio",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 613,
      "start_date": "2015-11",
      "completion_date": "2017-08-08",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 17,
      "location_summary": "Anaheim, California • Buena Park, California • Chula Vista, California + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02607618"
    },
    {
      "nct_id": "NCT02378480",
      "title": "Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Infections",
        "Skin Structures and Soft Tissue Infections"
      ],
      "interventions": [
        {
          "name": "Omadacycline",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paratek Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 655,
      "start_date": "2015-06",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-03-21",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Chula Vista, California • La Mesa, California + 14 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02378480"
    },
    {
      "nct_id": "NCT01170221",
      "title": "TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Skin and Subcutaneous Tissue Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "TR-701 FA",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 667,
      "start_date": "2010-08-15",
      "completion_date": "2011-09-30",
      "has_results": true,
      "last_update_posted_date": "2018-08-29",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 30,
      "location_summary": "Dothan, Alabama • Anaheim, California • Buena Park, California + 22 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Buena Park",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170221"
    },
    {
      "nct_id": "NCT02452918",
      "title": "A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Bacterial Skin and Skin Structure Infection"
      ],
      "interventions": [
        {
          "name": "Oritavancin",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2015-09-29",
      "completion_date": "2016-07-05",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 1,
      "location_summary": "Somers Point, New Jersey",
      "locations": [
        {
          "city": "Somers Point",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02452918"
    },
    {
      "nct_id": "NCT01252732",
      "title": "Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Wound Infection",
        "Abscess",
        "Systemic Inflammation",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Single-Dose IV Oritavancin Diphosphate",
          "type": "DRUG"
        },
        {
          "name": "IV Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinta Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1019,
      "start_date": "2010-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 1,
      "location_summary": "La Mesa, California",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01252732"
    },
    {
      "nct_id": "NCT01724671",
      "title": "Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "MRSA Infection",
        "Bacteremia",
        "ABSSSI",
        "Pneumonia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "CPL Associates",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2012-12",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2012-11-12",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01724671"
    },
    {
      "nct_id": "NCT04919954",
      "title": "Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Wound Infection",
        "ABSSSI",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tebipenem Pivoxil Hydrobromide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hartford Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2021-07-01",
      "completion_date": "2022-12-23",
      "has_results": false,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 1,
      "location_summary": "Hartford, Connecticut",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919954"
    },
    {
      "nct_id": "NCT02066402",
      "title": "Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "Tedizolid (BAY119-2631)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tedizolid (BAY119-2631)",
          "type": "DRUG"
        },
        {
          "name": "Linezolid",
          "type": "DRUG"
        },
        {
          "name": "Placebo Linezolid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 598,
      "start_date": "2014-03-04",
      "completion_date": "2016-04-18",
      "has_results": true,
      "last_update_posted_date": "2017-06-07",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 5,
      "location_summary": "Chula Vista, California • La Mesa, California • Oceanside, California + 2 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02066402"
    },
    {
      "nct_id": "NCT03747497",
      "title": "Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Skin Diseases, Bacterial",
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "contezolid acefosamil",
          "type": "DRUG"
        },
        {
          "name": "linezolid 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MicuRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2018-11-15",
      "completion_date": "2019-03-26",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-07-22T18:05:12.593Z",
      "location_count": 7,
      "location_summary": "Chula Vista, California • La Mesa, California • Long Beach, California + 3 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03747497"
    }
  ]
}